These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 10545714)

  • 1. Hypersensitivity and hyperreactivity in the irritable bowel syndrome: An opportunity for drug discovery.
    Sanger GJ
    Dig Dis; 1999; 17(2):90-9. PubMed ID: 10545714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of irritable bowel syndrome: novel approaches to the pharmacology of gut motility.
    Scarpignato C; Pelosini I
    Can J Gastroenterol; 1999 Mar; 13 Suppl A():50A-65A. PubMed ID: 10202210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irritable bowel syndrome: new pharmaceutical approaches to treatment.
    Farthing MJ
    Baillieres Best Pract Res Clin Gastroenterol; 1999 Oct; 13(3):461-71. PubMed ID: 10580922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.
    De Ponti F; Tonini M
    Drugs; 2001; 61(3):317-32. PubMed ID: 11293643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug treatment options for irritable bowel syndrome: managing for success.
    Dunphy RC; Verne GN
    Drugs Aging; 2001; 18(3):201-11. PubMed ID: 11302287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Approaches to the modulation of abdominal pain.
    Mayer EA; Lembo T; Chang L
    Can J Gastroenterol; 1999 Mar; 13 Suppl A():65A-70A. PubMed ID: 10202211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tegaserod: a new 5-HT4 agonist.
    Lacy BE; Yu S
    J Clin Gastroenterol; 2002 Jan; 34(1):27-33. PubMed ID: 11743242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Serotonin may be the key to the treatment of "irritable bowel disease"].
    Sjövall H
    Lakartidningen; 2001 May; 98(18):2166-71. PubMed ID: 11402594
    [No Abstract]   [Full Text] [Related]  

  • 9. Neuropathophysiology of irritable bowel syndrome.
    Wood JD
    J Clin Gastroenterol; 2002 Jul; 35(1 Suppl):S11-22. PubMed ID: 12184133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review article: 5-hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: clinical implications.
    Talley NJ
    Aliment Pharmacol Ther; 1992 Jun; 6(3):273-89. PubMed ID: 1600046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug therapy options for patients with irritable bowel syndrome.
    Talley NJ
    Am J Manag Care; 2001 Jul; 7(8 Suppl):S261-7. PubMed ID: 11474911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of sex and gender on irritable bowel syndrome.
    Heitkemper M; Jarrett M; Bond EF; Chang L
    Biol Res Nurs; 2003 Jul; 5(1):56-65. PubMed ID: 12886671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Functional diarrhea - pathophysiology, investigation and treatment].
    Schaub N; Degen L
    Ther Umsch; 2014 Sep; 71(9):551-8. PubMed ID: 25154691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Colonic motility in humans. Recent physiological, pathophysiological and pharmacological data].
    Jouët P; Coffin B; Cuillerier E; Soulé JC; Flourié B; Lémann M
    Gastroenterol Clin Biol; 2000 Mar; 24(3):284-98. PubMed ID: 10804335
    [No Abstract]   [Full Text] [Related]  

  • 15. Tegaserod and other serotonergic agents: what is the evidence?
    Chey WD
    Rev Gastroenterol Disord; 2003; 3 Suppl 2():S35-40. PubMed ID: 12776001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update in the therapeutic management of irritable bowel syndrome.
    Villanueva A; Domínguez-Muñoz JE; Mearin F
    Dig Dis; 2001; 19(3):244-50. PubMed ID: 11752844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging treatments for irritable bowel syndrome.
    Ahn J; Ehrenpreis ED
    Expert Opin Pharmacother; 2002 Jan; 3(1):9-21. PubMed ID: 11772329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review article: the therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome.
    Humphrey PP; Bountra C; Clayton N; Kozlowski K
    Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():31-8. PubMed ID: 10429738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel therapies in the treatment of irritable bowel syndrome.
    Berrada D; Lembo T
    Expert Opin Investig Drugs; 2003 Apr; 12(4):635-45. PubMed ID: 12665418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroanatomy of lower gastrointestinal pain disorders.
    Vermeulen W; De Man JG; Pelckmans PA; De Winter BY
    World J Gastroenterol; 2014 Jan; 20(4):1005-20. PubMed ID: 24574773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.